miR-376b and miR-4668 predict therapeutic response to sunitinib
in metastatic renal cell carcinoma

a 2019

miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, O. FIALA et. al.

Basic information

Original name

miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma

Authors

BOHOŠOVÁ, Júlia (703 Slovakia, belonging to the institution), Jaroslav JURÁČEK (203 Czech Republic, belonging to the institution), Alexandr POPRACH (203 Czech Republic, belonging to the institution), T. BUCHLER, O. FIALA, Lenka RADOVÁ (203 Czech Republic, belonging to the institution), Marek SVOBODA (203 Czech Republic, belonging to the institution), Alena KOPKOVÁ (203 Czech Republic, belonging to the institution), Marek VEČEŘA (703 Slovakia, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution)

Edition

AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, 2019

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 9.727

RIV identification code

RIV/00216224:14740/19:00108622

Organization unit

Central European Institute of Technology

ISSN

DOI

http://dx.doi.org/10.1158/1538-7445.AM2019-1800

UT WoS

000488129904321

Keywords in English

miR-376b; miR-4668

Abstract

V originále

Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.

Links

NV18-03-00554, research and development project

Name: Molekulární klasifikace renálního buněčného karcinomu založená na expresi dlouhých nekódujících RNA a její využití v diagnostice, předpovědi prognózy a terapii

Investor: Ministry of Health of the CR

Citovat

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, O. FIALA, Lenka RADOVÁ, Marek SVOBODA, Alena KOPKOVÁ, Marek VEČEŘA and Ondřej SLABÝ. miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma. In AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology. 2019. ISSN 0008-5472. Available from: https://dx.doi.org/10.1158/1538-7445.AM2019-1800.

@proceedings{1642624,
   author = {Bohošová, Júlia and Juráček, Jaroslav and Poprach, Alexandr and Buchler, T. and Fiala, O. and Radová, Lenka and Svoboda, Marek and Kopková, Alena and Večeřa, Marek and Slabý, Ondřej},
   booktitle = {AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology},
   doi = {http://dx.doi.org/10.1158/1538-7445.AM2019-1800},
   keywords = {miR-376b; miR-4668},
   language = {eng},
   title = {miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma},
   year = {2019}
}

TY  - CONF
ID  - 1642624
AU  - Bohošová, Júlia - Juráček, Jaroslav - Poprach, Alexandr - Buchler, T. - Fiala, O. - Radová, Lenka - Svoboda, Marek - Kopková, Alena - Večeřa, Marek - Slabý, Ondřej
PY  - 2019
TI  - miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma
KW  - miR-376b
KW  - miR-4668
N2  - Metastatic renal cell carcinoma (mRCC) is routinely treated with sunitinib, a tyrosine kinase inhibitor (TKI) of VEGF signalisation. Although disease eventually progresses in most mRCC patients, length of progression-free survival (PFS) is ranging from few weeks up to more than 24 months. Patients with initial resistance to sunitinib could be redirected to other therapeutical options, as there are several other TKIs available for use in second and third line. However, without a reliable biomarker no result can be predicted. MicroRNAs (miRNAs) belong to class of short non-coding RNAs and could serve as biomarkers of therapy response due to their unique character and presence in tissues and body fluids. Their biomarker potential has been discussed concerning many diseases including mRCC, but current knowledge is very weak, has several discrepancies and is acquired on relatively small cohorts.
ER  -

BOHOŠOVÁ, Júlia, Jaroslav JURÁČEK, Alexandr POPRACH, T. BUCHLER, O. FIALA, Lenka RADOVÁ, Marek SVOBODA, Alena KOPKOVÁ, Marek VEČEŘA and Ondřej SLABÝ. miR-376b and miR-4668 predict therapeutic response to sunitinib in metastatic renal cell carcinoma. In \textit{AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology}. 2019. ISSN~0008-5472. Available from: https://dx.doi.org/10.1158/1538-7445.AM2019-1800.

Detailed Information on Publication Record